✅ Need to return for the injection every 12 weeks — INCLUDE
➡️ DMPA is a long-acting progestin-only injectable contraceptive, so it does not require daily administration.
➡️ The standard DMPA-IM dose is 150 mg intramuscularly approximately every 3 months.
➡️ Current CDC guidance describes the routine reinjection interval as 13 weeks; many nursing resources describe this generally as approximately 12–13 weeks or every 3 months.
➡️ Maintaining the injection schedule is important because contraceptive effectiveness depends on receiving subsequent doses at the appropriate intervals.
➡️ CDC guidance allows a repeat DMPA injection to be given up to 15 weeks after the previous injection without requiring additional contraceptive protection.
➡️ If the client presents later than the recommended grace period, pregnancy should be reasonably excluded and temporary backup contraception may be necessary.
➡️ This method is particularly useful for this client because she has difficulty remembering a daily contraceptive pill.
➡️ The injection also avoids estrogen, which is important given her elevated blood pressure and history of headaches with visual symptoms.
✅ Report progressive weight gain — INCLUDE
➡️ Weight gain is a recognized adverse effect of DMPA and should be discussed during client teaching.
➡️ Clinical trials have demonstrated progressive average weight gain among some clients receiving DMPA.
➡️ Pfizer reports an average gain of approximately 5.4 lb during the first year among women completing one year of treatment.
➡️ Weight gain can become more substantial with continued treatment, although individual responses vary considerably.
➡️ The nurse should encourage the client to monitor changes in body weight during therapy.
➡️ Significant or progressive weight gain should be discussed with the healthcare provider so that nutrition, activity, other medical causes, and continued contraceptive choice can be reviewed.
➡️ Healthy dietary habits and regular physical activity can help support appropriate weight management.
➡️ Weight gain does not automatically require discontinuation, but unexpected or excessive changes warrant evaluation.
✅ Increase consumption of calcium-containing foods — INCLUDE
➡️ DMPA is associated with a reduction in bone mineral density (BMD) during use.
➡️ The effect occurs because DMPA suppresses ovarian estrogen production, and estrogen plays an important role in maintaining bone mass.
➡️ Clinical studies have demonstrated decreases in bone mineral density of the lumbar spine and hip during prolonged DMPA use.
➡️ Adequate dietary calcium helps support bone mineralization and skeletal health.
➡️ Appropriate sources include milk, yogurt, cheese, calcium-fortified foods, and certain green vegetables, depending on the client's diet.
➡️ Adequate vitamin D is also important because it facilitates intestinal calcium absorption.
➡️ Pfizer prescribing information specifically recognizes bone mineral density loss as an important consideration with DMPA therapy.
➡️ Therefore, maintaining adequate calcium and vitamin D intake is appropriate health teaching for a client receiving DMPA.
✅ Begin regular weight-bearing exercise — INCLUDE
➡️ Weight-bearing exercise is encouraged because DMPA can decrease bone mineral density.
➡️ Exercises such as walking, jogging, stair climbing, dancing, and resistance training place healthy mechanical stress on bones.
➡️ This stimulation helps support bone remodeling and maintenance of bone strength.
➡️ Exercise works together with adequate calcium and vitamin D intake to support bone health.
➡️ Regular activity also provides cardiovascular and metabolic benefits and may assist with weight management, another relevant concern with DMPA.
➡️ Bone-density loss tends to be more pronounced during the earlier years of DMPA use, although some recovery can occur after discontinuation.
➡️ Clients with other osteoporosis risk factors may require additional individualized assessment.
➡️ Therefore, regular weight-bearing activity is an important component of DMPA client education.
❌ May experience withdrawal bleeding after 21 days — DO NOT INCLUDE
➡️ Predictable withdrawal bleeding after approximately 21 active pills is associated with traditional cyclic combined oral contraceptive regimens.
➡️ DMPA is an injectable progestin-only contraceptive and is not administered on a 21-day oral medication cycle.
➡️ DMPA commonly causes irregular spotting or light bleeding, particularly during the early months of use.
➡️ Some clients can also experience heavy or prolonged bleeding.
➡️ With continued use, many clients eventually develop amenorrhea.
➡️ These bleeding changes are generally not harmful but should be explained before treatment to reduce concern.
➡️ CDC guidance specifically identifies amenorrhea, spotting, and irregular bleeding as expected patterns with DMPA.
➡️ Therefore, teaching the client to expect withdrawal bleeding specifically after 21 days would be inaccurate.
❌ Back-up contraception if prescribed an antibiotic — DO NOT INCLUDE as a general rule
➡️ Routine broad-spectrum antibiotics do not significantly reduce the effectiveness of DMPA.
➡️ The client therefore does not automatically need an additional contraceptive method merely because an antibiotic has been prescribed.
➡️ CDC guidance classifies broad-spectrum antibiotic use with DMPA as having no restriction related to contraceptive effectiveness.
➡️ Even medications such as rifampin or rifabutin, which can reduce the effectiveness of some hormonal contraceptives, do not have the same clinically important effect on DMPA's contraceptive effectiveness.
➡️ Backup contraception is needed in certain circumstances related to when DMPA is initiated or when injections are substantially late, rather than simply because an antibiotic is prescribed.
➡️ For example, when the first DMPA injection is given more than 7 days after menstrual bleeding started, CDC recommends abstinence or barrier contraception for the next 7 days.
➡️ Condoms remain appropriate for STI prevention, because DMPA does not protect against sexually transmitted infections.
➡️ Therefore, the broad statement that antibiotics require backup contraception should not be included.
❌ Fertility impacted up to 6 months after stopping — DO NOT INCLUDE because the timeframe is inaccurate
➡️ DMPA can cause a delayed return of ovulation and fertility after the injections are stopped.
➡️ The delay is clinically important for this client because she plans another pregnancy in approximately 1½–2 years.
➡️ The statement saying fertility is affected only up to 6 months understates how long the delay can last.
➡️ Pfizer reports that the median time to conception is approximately 10 months after the last DMPA injection among clients who eventually conceived.
➡️ Approximately 68% of those who conceived did so within 12 months, 83% within 15 months, and 93% within 18 months after their last injection.
➡️ CDC evidence also shows substantial variation in the return of ovulation after the final injection.
➡️ Therefore, clients should understand that fertility may remain delayed for many months, potentially longer than 6 months.
➡️ This delayed return to fertility is different from permanent infertility; DMPA is reversible, but fertility may not return immediately.